Investigating the Groundbreaking Potential of Anti-CTGF Therapy

Pamrevlumab is a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF). CTGF is a common factor in chronic fibrotic and proliferative disorders, characterized by persistent and excessive fibrous tissue which can lead to organ dysfunction and failure, and in cancer, characterized by promotion of tumor growth. Pamrevlumab is in Phase 3 clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and idiopathic pulmonary fibrosis (IPF). The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pamrevlumab for the treatment of patients with LAPC, DMD, and IPF. Pamrevlumab has also received Fast Track designation from the U.S. Food and Drug Administration for the treatment of patients with LAPC and IPF. Across all clinical studies to date, pamrevlumab has consistently demonstrated a good safety and tolerability profile. For information about pamrevlumab studies currently recruiting patients, please visit


Pamrevlumab Trials

Developing unprecedented options for patients with IPF.